House members were quick to frame FDA user fee reauthorization legislation as one answer to drug pricing problems as they passed the bill July 12.
Titled the FDA Reauthorization Act (FDARA), the bill includes the formal user fee program renewals, as well as several policy changes. (See chart below).
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?